A case of infant botulism in a 4-month-old baby by Dilettta, Sabatini et al.
C A S E R E P O R T
A case of infant botulism in a 4-month-old baby
D. Sabatini1, L. Papetti2, D. Lonati3, F. Anniballi4, B. Auricchio4, E. Properzi2
and M.C. Grassi1
From the 1Emergency Toxicology and Poison Control Centre Unit, Umberto I Policlinico of Rome and Sapienza
University of Rome, Italy, 2Department of Pediatrics, Sapienza University of Rome, Italy, 3Poison Control
Centre and National Toxicology Information Centre, Toxicology Unit, IRCCS Maugeri Foundation, Pavia, Italy
and 4Department of Veterinary Public Health and Food Safety, National Reference Centre for Botulism, Istituto
Superiore di Sanita`, Rome, Italy
Address correspondence to M.C. Grassi, Emergency Toxicology and Poison Control Centre Unit, Umberto I Policlinico of Rome, Department of Physiology and
Pharmacology “V. Erspamer” - Sapienza University of Rome, School of Medicine, Piazzale Aldo Moro 5, 00185 Rome, Italy. email: caterina.grassi@uniroma1.it
Learning point for clinicians
This case report highlights: (i) the difficulty of infant
botulism (IB) diagnosis as it is a rare disease, (ii) the effi-
cacy and safety of trivalent equine antitoxin in IB treat-
ment, (iii) honey is not the only cause of IB and (iv) the
need for physician training to recognize and diagnose IB.
Case presentation
A 4-month-old baby (7 kg) was admitted to the Pediatric
Department for constipation, feeding difficulties, weak cry, leth-
argy and weak muscular body control. Symptoms of infant
botulism (IB) appeared 1 month before the admission, after
hexavalent vaccine administration, with a slow and progressive
evolution. The baby has become lethargic, with blunted facial
expression and weak cry. Seven days before admission he
started refusing breast milk. Clinical history revealed no
perinatal or delivery complications and the baby was normal for
development and growth (50th percentile). On admission the
baby was fully conscious and the initial exam confirmed gener-
alized but moderate hypotonia, bilateral ptosis and strabismus.
The tendon reflexes remained symmetric. Pediatricians sus-
pected a cerebral infectious disease; therefore, dexamethasone
ceftriaxone, acyclovir and dextrose were administered. The
laboratory and radiological exams showed no abnormalities as
well as cerebrospinal analysis; viral and metabolic tests were
normal. Clinical course improved quickly and the baby was dis-
charged after 1 week. Since constipation and bilateral ptosis
were not completely resolved, a follow-up visit was planned in
10 days. At the time of follow-up symptoms were still observed.
Therefore, the baby was re-hospitalized for further examin-
ation. On the second day, the clinical condition worsened in
that oxygen desaturation, generalized and severe hypotonia
and non-reactive bilateral mydriasis appeared. The baby
refused breastfeeding and enteral nutrition was started.
Electromyography confirmed presynaptic block. Given the clin-
ical scenario, IB was suspected.
Clinical samples were submitted for laboratory confirmation
at the National Reference Centre for Botulism and Clostridium
botulinum type A was detected in rectal swabs and enema via
real-time Polimerase Chain Reaction (PCR). No botulinum neuro-
toxins (BoNTs) were detected in enema. Spores excretion became
negative 4 days after the laboratory confirmation. History re-
vealed that the child had ingested honey 5 days prior to the onset
of symptoms. However, analysis of leftover honey resulted nega-
tive for C. botulinum spores. The patient was transferred to the
Pediatric Intensive Care Unit. Upon indication of Rome and Pavia
Poison Control Centres, trivalent equine antitoxin (Botulism
Antitoxin Behring: 750 IU-anti-A, 500 IU-anti-B, 50 IU-anti-E/ml;
10 ml/kg/iv) was administered. Clinical conditions improved 48 h
later and the baby was moved to the Pediatric Department after
10 days. Enteral nutrition was required for 3 weeks. The baby
was discharged without sequelae after 1 month.
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Discussion
IB is a life-threatening disease that results from absorption of
BoNTs produced in situ by clostridia that colonize the intestinal
lumen of infants below 1 year of age.1 Colonization occurs be-
cause normal bowel florae that could compete with clostridia
have not been fully established.2 BoNTs cause muscle flaccid
paralysis through presynaptic blockade of acetylcholine re-
lease.1 The clinical onset is insidious and characterized by con-
stipation, weak cry, difficulty in breastfeeding, poor muscle
tone and finally paralysis of the respiratory muscles. The diag-
nosis is frequently delayed. The identified risk’s factors for IB
are honey, and spores coming from telluric environments or
herbal infusion (i.e. dust, chamomile).2 IB is a rare but generally
reversible disease, and antidotal therapy is required in selected
cases.3 Different antitoxin formulations are available for botu-
lism.3,4 The treatment with trivalent equine antitoxin showed
no acute or delayed adverse reactions and represents an effect-
ive method for rapidly reversing IB.3,5 In USA, Baby-BIG, human-
derived botulism antitoxin, is the antitoxin of choice for IB’s
treatment, but the high cost limits its use in many countries.6 In
other countries, equine antitoxin is currently used and con-
sidered safe and effective.3,5
Despite honey ingestion is among the most common cause
of IB, this was not the cause. We hypothesize that the probable
source of C. botulinum spores was the dust settled on the clothes
of baby’s father who worked as a bricklayer and was use to cra-
dle the baby in his arms coming back home.
In conclusion, this case report suggests that diagnosis of IB
must be considered even when no history of honey intake is re-
ported, and also highlights the need for physician to receive ad-
equate training to recognize and diagnose IB.
Conflict of interest: None declared.
References
1.Fenicia L, Anniballi F. Infant botulism. Ann Ist Super Sanita
2009; 45:134–46.
2.Brook I. Infant botulism. J Perinatol 2007; 27:175–80.
3.Lonati D, Fenicia L, Petrolini V, Giampreti A, Anniballi F,
Vecchio S,et al. Dose adjustment of trivalent equine anti-
toxin in the treatment of infant botulism. Clin Toxicol 2012;
50:317–8.
4.Anniballi F, Lonati D, Fiore A, Auricchio B, De Medici D,
Locatelli CA. New targets in the search for preventive and
therapeutic agents for botulism. Expert Rev Anti Infect Ther 2014;
12:1075–86.
5.Vanella de Cuetos EE, Fernandez RA, Bianco MI, Sartori OJ,
Piovano ML, Luquez C, et al. Equine botulinum antitoxin for the
treatment of infant botulism. Clin Vaccine Immunol 2011; 18:
1845–9.
6.Arnon SS, Schechter R, Maslanka SE, Jewell NP, Hatheway CL.
Human botulism immune globulin for the treatment of infant
botulism. N Engl J Med 2006; 354:462–71.
2 | QJM: An International Journal of Medicine, 2015, Vol. 0, No. 0
by guest on April 27, 2015
D
ow
nloaded from
 
